Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending July 18, 2016. The document serves as a transaction notification regarding a Person Discharging Managerial Responsibilities (PDMR) or a person closely associated with them, rather than a periodic financial report.
Key Financial Metrics
The filing does not provide consolidated financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data present relates to a specific share transaction:
- Instrument: Ordinary shares of 25 pence each (ISIN: GB0009252882).
- Transaction Price: £16.6781 per share.
- Transaction Volume: 565,204 shares.
Material Changes
The filing reports a single transaction involving the acquisition of Ordinary Shares by Ms. C Thomas, SVP of HR. This acquisition resulted from the re-investment of dividends paid to shareholders on July 14, 2016. There are no reported material changes to the company's financial position or operations in this document.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, contingencies, or unusual items. It is strictly a regulatory disclosure of a specific share transaction executed on the London Stock Exchange (XLON).
Investor Verification Points
- Verify the identity of the PDMR involved: Ms. C Thomas, SVP, HR.
- Confirm the transaction date of July 14, 2016, and the execution venue (London Stock Exchange).
- Note that this filing does not contain quarterly or annual financial performance data; investors should refer to Form 20-F for comprehensive financial results.